PARIS–(BUSINESS WIRE)–LimFlow SA, ontwikkelaar van innovatieve, perifere endovasculaire technologie die de behandeling van critical limb ischemia (CLI) verandert, kondigt vandaag aan dat het 27 miljoen euro heeft veiliggesteld in een overtekende C-financiering. De ronde werd geleid door Sofinnova Partners, met voortdurende deelname van bestaande round B-investeerders als Bpifrance, de Franse soevereine investeringsbank en Balestier, een Singaporees familiefonds. Gérard Hascöet, Venture Partner bij Sofinnova Partners en dr. Kinam Hong, Partner van het Sofinnova Crossover I Fund, zullen toetreden tot de raad van bestuur. Het is de eerste investering voor het nieuw opgerichte Sofinnova Crossover I Fund.

Opbrengsten uit de serie C-financiering zullen de belangrijkste strategische initiatieven van het bedrijf financieren in de tweede helft van 2020, inclusief de voltooiing van een Amerikaanse hoofdstudie voor het LimFlow Percutaneous Deep Vein Arterialization System (pDVA), dat zal worden voorgelegd aan de FDA als onderdeel van het goedkeuringsproces en de uitvoering van zijn internationale commercialiseringsstrategie.

LimFlow Raises €27 Million ($33.5 Million) in Series C Financing Led by Sofinnova Partners to Advance Innovative Critical Limb Ischemia (CLI) Treatment

PARIS–(BUSINESS WIRE)–LimFlow SA, developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia (CLI), today announced it has secured €27 million ($33.5 million) in an oversubscribed Series C financing. The round was led by Sofinnova Partners, with continued participation from existing round B investors Bpifrance, the French sovereign investment bank, and Balestier, a Singaporean family fund. Gérard Hascöet, Venture Partner at Sofinnova Partners, and Dr. Kinam Hong, Partner of the Sofinnova Crossover I Fund, will join the company’s board of directors. The investment is the first for the newly raised Sofinnova Crossover I Fund.

Proceeds from the Series C financing will fund the company’s major strategic initiatives through the second half of 2020, including completion of a U.S. pivotal trial for the LimFlow Percutaneous Deep Vein Arterialization System (pDVA), which will be submitted to the FDA as part of the approval process, and execution of its international commercialization strategy.

Based in Paris, LimFlow was founded in late 2012 by Dr. Martin Rothman, a world-renowned interventional cardiologist, and MD Start, a European Incubator dedicated to healthcare. The company’s proprietary and CE marked technology is a novel and purely percutaneous therapy for “no-option” CLI patients when all other revascularization efforts have been exhausted and a patient is facing a major amputation.

In the past 18 months, the company has achieved a number of key milestones, including CE Mark and acceptance into the FDA Breakthrough Devices Program. Enrollment is also currently underway in both a U.S. feasibility study of the LimFlow technology (PROMISE I) and an international post-market study (PROMISE International).

“We are gratified with the support we have received from Sofinnova Partners, a leading European venture capital firm and one of the most respected and specialized global Life Sciences investors. We are equally appreciative of the continued strong commitment from our existing investors. The new funds will enable us to continue our mission to save patients from amputation, and ultimately, save lives that might otherwise be lost,” said LimFlow CEO Dan Rose.

“LimFlow is an excellent fit for our healthcare Crossover I fund, where we seek investments in companies with game-changing technologies that address important clinical unmet needs and are led by experienced and passionate management teams,” said Dr. Hong.

CAUTION: The LimFlow technology is approved for investigational use only in the United States. The LimFlow System received the CE Mark in October 2016 and is currently available commercially in Europe. The LimFlow System has not been approved for sale in the USA, Canada, or Japan.